公开(公告)号：US20230399298A1

公开(公告)日：2023-12-14

申请号：US18251313

申请日：2021-10-27

申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

发明人： Jaeeun Kim ,  Jaemin Lee ,  Dong Hyuk Nam ,  So Hyun Park ,  Sung Kwon Kang ,  Shin Jung Park

IPC分类号： C07D211/22

CPC分类号： C07D211/22

摘要： The present invention relates to donepezil ether palmitate hydrochloride (DEP HCl) and a method for preparing same. Donepezil ether palmitate hydrochloride (DEP HCl) has been developed to have increased stability by suppressing generation of unknown related substances generated during a preparation process of a raw material and formulation of donepezil ether palmitate (DEP). In addition, the present invention relates to a sustained-release pharmaceutical composition comprising donepezil ether palmitate hydrochloride (DEP HCl) as a main ingredient. When administered in the body, the initial release of donepezil, which is an active ingredient, is reduced, thereby reducing the risk of side effects such as drug toxicity, and the constant release of donepezil in the body for a long period of time can improve the drug treatment effect on dementia patients.

公开(公告)号：US11718638B2

公开(公告)日：2023-08-08

申请号：US16624896

申请日：2018-06-21

申请人： WAVE LIFE SCIENCES LTD.

发明人： David Charles Donnell Butler ,  Christopher P. Hencken ,  Naoki Iwamoto ,  Pachamuthu Kandasamy ,  Alvaro Andres Lanao ,  Genliang Lu ,  Mamoru Shimizu ,  Sethumadhavan Divakaramenon ,  Chandra Vargeese ,  Gopal Reddy Bommineni ,  Subramanian Marappan

IPC分类号： C07H21/04 ,  C07H19/06 ,  C07C213/00 ,  C07C215/20 ,  C07C215/44 ,  C07D207/08 ,  C07D211/22 ,  C07F7/08 ,  C07F9/6564

CPC分类号： C07H21/04 ,  C07C213/00 ,  C07C215/20 ,  C07C215/44 ,  C07D207/08 ,  C07D211/22 ,  C07F7/083 ,  C07F7/0812 ,  C07F9/6564 ,  C07H19/06 ,  C07C2601/14

摘要： The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

公开(公告)号：US20230203002A1

公开(公告)日：2023-06-29

申请号：US17879923

申请日：2022-08-03

申请人： Trevena, Inc.

发明人： Aimee Crombie Speerschneider ,  Dennis Shinji Yamashita ,  Philip Michael Pitis ,  Michael John Hawkins ,  Guodong Liu ,  Tamara Ann Miskowski Daubert ,  Catherine C.K. Yuan ,  Robert Borbo Kargbo ,  Robert Jason Herr ,  Donna Romero ,  Gregory J. Pacofsky

IPC分类号： C07D401/12 ,  A61K31/445 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D241/04 ,  C07D451/02 ,  C07D211/22

CPC分类号： C07D401/12 ,  A61K31/445 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D241/04 ,  C07D451/02 ,  C07D211/22

摘要： The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.

公开(公告)号：US11673852B2

公开(公告)日：2023-06-13

申请号：US17713446

申请日：2022-04-05

申请人： ZOGENIX INTERNATIONAL LIMITED

发明人： Stephen J. Farr ,  Brooks M. Boyd

IPC分类号： C07C211/29 ,  A61K31/137 ,  A61K45/06 ,  C07D211/22 ,  C07C215/64 ,  C07D221/18 ,  C07D207/08 ,  A61P25/08

CPC分类号： C07C211/29 ,  A61K31/137 ,  A61K45/06 ,  A61P25/08 ,  C07C215/64 ,  C07D207/08 ,  C07D211/22 ,  C07D221/18 ,  C07C2601/04 ,  C07C2601/14

摘要： Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.

公开(公告)号：US11655216B2

公开(公告)日：2023-05-23

申请号：US16341595

申请日：2017-10-09

申请人： Merck Sharp & Dohme Corp. ,  Michael T. Rudd ,  Zhaoyang Meng ,  Jenny Wai ,  David Jonathan Bennett ,  Edward J. Brnardic ,  Nigel J. Liverton ,  Shawn J. Stachel ,  Yongxin Han ,  Paul Tempest ,  Jiuxiang Zhu ,  Xuewang Xu ,  Bin Zhu

发明人： Michael T. Rudd ,  Zhaoyang Meng ,  Jenny Wai ,  David Jonathan Bennett ,  Edward J. Brnardic ,  Nigel J. Liverton ,  Shawn J. Stachel ,  Yongxin Han ,  Paul Tempest ,  Jiuxiang Zhu ,  Xuewang Xu ,  Bin Zhu

IPC分类号： C07D221/20 ,  C07D401/12 ,  C07D417/12 ,  C07D405/12 ,  C07D211/22 ,  C07D401/14 ,  C07D417/14

CPC分类号： C07D221/20 ,  C07D211/22 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D417/12 ,  C07D417/14

摘要： In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

公开(公告)号：US20220356204A1

公开(公告)日：2022-11-10

申请号：US16624896

申请日：2018-06-21

申请人： David Charles Donnell BUTLER ,  Christopher P. HENCKEN ,  Nao-ki IWAMOTO ,  Pachamuthu KANDASAMY ,  Alvaro Andres LANAO ,  Genliang LU ,  Mamoru SHIMIZU ,  Sethumadhavan DIVAKARAMENON ,  Chandra VARGEESE ,  Gopal Reddy BOMMINENI ,  Subramanian MARAPPAN ,  WAVE LIFE SCIENCES LTD.

发明人： David Charles Donnell Butler ,  Christopher P. Hencken ,  Naoki Iwamoto ,  Pachamuthu Kandasamy ,  Alvaro Andres Lanao ,  Genliang Lu ,  Mamoru Shimizu ,  Sethumadhavan Divakaramenon ,  Chandra Vargeese ,  Gopal Reddy Bommineni ,  Subramanian Marappan

IPC分类号： C07H21/04 ,  C07F7/08 ,  C07D207/08 ,  C07H19/06 ,  C07C215/20 ,  C07C213/00 ,  C07D211/22 ,  C07C215/44

摘要： The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

公开(公告)号：US20220356153A1

公开(公告)日：2022-11-10

申请号：US17537110

申请日：2021-11-29

申请人： COGNITION THERAPEUTICS, INC.

发明人： Gilbert M. RISHTON ,  Gary C. LOOK ,  Susan M. CATALANO

IPC分类号： C07D205/04 ,  C07D207/08 ,  C07D207/16 ,  C07D211/22 ,  C07D211/46 ,  C07D211/48 ,  C07D241/04 ,  C07D241/08 ,  C07D265/30 ,  C07D401/04 ,  C07D403/06 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D413/14 ,  C07D491/107

摘要： The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.

公开(公告)号：US11409194B2

公开(公告)日：2022-08-09

申请号：US16530438

申请日：2019-08-02

申请人： Shin-Etsu Chemical Co., Ltd.

发明人： Jun Hatakeyama ,  Masaki Ohashi ,  Takayuki Fujiwara

IPC分类号： G03F7/004 ,  G03F7/038 ,  C07D295/088 ,  C07C217/06 ,  C07D235/12 ,  C07D211/22 ,  C07D207/08 ,  C07D211/46 ,  C07D453/02 ,  C07D209/52 ,  C07D451/02 ,  G03F7/039 ,  G03F7/32 ,  G03F7/16 ,  G03F7/20 ,  G03F7/38

摘要： A resist composition comprising a base polymer and a quencher in the form of an amine compound having an iodized aromatic ring bonded to the nitrogen atom via a divalent hydrocarbon group offers a high sensitivity and minimal LWR or improved CDU, independent of whether it is of positive or negative tone.

公开(公告)号：US11298326B2

公开(公告)日：2022-04-12

申请号：US15560854

申请日：2016-03-24

申请人： Kyowa Kirin Co., Ltd.

发明人： Kentaro Hatanaka ,  Nobuhiro Yagi ,  Takeshi Kuboyama ,  Kaori Yagi ,  Shintaro Hosoe

IPC分类号： A61K9/51 ,  C07C217/28 ,  A61K9/127 ,  C07D223/04 ,  C07C229/12 ,  A61K31/713 ,  A61P29/00 ,  C07C237/22 ,  C07D401/04 ,  A61K9/00 ,  C07D295/088 ,  C07D207/12 ,  A61P35/00 ,  C07D317/28 ,  C07D211/22 ,  C07D207/08 ,  C12N15/11 ,  A61K31/7088 ,  C07C211/63 ,  C07C215/08 ,  C07C219/08 ,  C07C229/06 ,  C07C233/20 ,  C07C237/08 ,  C07C271/16 ,  C07D451/14 ,  C12N15/113

摘要： The present invention provides nucleic acid-containing lipid nanoparticles containing a lipid (lipid A) which has a hydrophilic unit having a single quaternary ammonium group, and three independent, optionally substituted hydrocarbon groups, a lipid derivative or fatty acid derivative of a water-soluble polymer, and a nucleic acid.

公开(公告)号：US20220062257A1

公开(公告)日：2022-03-03

申请号：US17349255

申请日：2021-06-16

申请人： Lophora ApS

发明人： Jesper Langgaard KRISTENSEN ,  Anders Asbjørn Jensen ,  Emil Märcher-Rørsted ,  Sebastian Leth-Petersen

IPC分类号： A61K31/452 ,  A61P25/24 ,  A61K31/397 ,  A61K31/40 ,  A61K31/451 ,  C07D205/04 ,  C07D207/08 ,  C07D211/22 ,  C07D211/34

摘要： The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.